학술논문

Evaluation of SARS-CoV-2 serology assays reveals a range of test performance
Document Type
article
Source
Nature Biotechnology. 38(10)
Subject
Biological Sciences
Biomedical and Clinical Sciences
Clinical Sciences
Biodefense
Pneumonia & Influenza
Prevention
Clinical Research
Infectious Diseases
Lung
Vaccine Related
Pneumonia
Emerging Infectious Diseases
Detection
screening and diagnosis
4.1 Discovery and preclinical testing of markers and technologies
4.2 Evaluation of markers and technologies
Infection
Good Health and Well Being
Adult
Aged
Aged
80 and over
Antibodies
Viral
Betacoronavirus
Biotechnology
COVID-19
COVID-19 Testing
Chromatography
Affinity
Clinical Laboratory Techniques
Coronavirus Infections
Enzyme-Linked Immunosorbent Assay
Female
Humans
Immunoglobulin G
Immunoglobulin M
Male
Middle Aged
Pandemics
Pneumonia
Viral
Point-of-Care Testing
Reverse Transcriptase Polymerase Chain Reaction
SARS-CoV-2
Sensitivity and Specificity
Young Adult
Language
Abstract
Appropriate use and interpretation of serological tests for assessments of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposure, infection and potential immunity require accurate data on assay performance. We conducted a head-to-head evaluation of ten point-of-care-style lateral flow assays (LFAs) and two laboratory-based enzyme-linked immunosorbent assays to detect anti-SARS-CoV-2 IgM and IgG antibodies in 5-d time intervals from symptom onset and studied the specificity of each assay in pre-coronavirus disease 2019 specimens. The percent of seropositive individuals increased with time, peaking in the latest time interval tested (>20 d after symptom onset). Test specificity ranged from 84.3% to 100.0% and was predominantly affected by variability in IgM results. LFA specificity could be increased by considering weak bands as negative, but this decreased detection of antibodies (sensitivity) in a subset of SARS-CoV-2 real-time PCR-positive cases. Our results underline the importance of seropositivity threshold determination and reader training for reliable LFA deployment. Although there was no standout serological assay, four tests achieved more than 80% positivity at later time points tested and more than 95% specificity.